ABT-724 is a drug which acts as a
dopamine agonist, and is selective for the
D4 subtype.[1] It was developed as a possible drug for the treatment of
erectile dysfunction,[2] although poor oral bioavailability means alternative drugs such as
ABT-670 may be more likely to be developed commercially.[3] Nonetheless, it continues to be used in scientific research into the function of the D4 receptor.[4][5]
^Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, et al. (July 2004). "Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction". Journal of Medicinal Chemistry. 47 (15): 3853–3864.
doi:
10.1021/jm030505a.
PMID15239663.
^Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, et al. (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–7465.
doi:
10.1021/jm060662k.
PMID17149874.